Access cutting-edge diffuse large b-cell lymphoma treatment through this clinical trial at a research site in Glendale. Study-provided care at no cost to qualified participants.
Access diffuse large b-cell lymphoma specialists in Glendale at no cost
This study follows strict safety protocols and ethical guidelines
All study-related diffuse large b-cell lymphoma treatment provided free
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in combination with rituximab, gemcitabine, and oxal
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this diffuse large b-cell lymphoma clinical trial in Glendale, AZ
If you're searching for diffuse large b-cell lymphoma treatment options in Glendale, AZ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Glendale research site is actively enrolling participants for this clinical trial. You'll receive care from experienced diffuse large b-cell lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.